Last reviewed · How we verify
Pf-07264660 (pf-07264660)
The mechanism of action of PF-07264660 is not specified.
PF-07264660, developed by Pfizer, holds a niche market position with two approved indications but no clinical trials reported, and it is not the world's best-selling drug. Its competitive advantage is less clear compared to other Pfizer products like Tilrekimig and Ompekimig, which block multiple cytokines, and external competitors such as Dupixent and Tezspire, which have well-defined mechanisms of action. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader market adoption. The pipeline outlook includes several Pfizer candidates that target overlapping pathways, suggesting a strategic focus on enhancing efficacy through multi-cytokine inhibition.
At a glance
| Generic name | pf-07264660 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Unfortunately, the mechanism of action of PF-07264660 is not provided in the available information. This makes it difficult to understand how the drug works and its potential benefits and risks. More research is needed to determine the exact mechanism of action.
Approved indications
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C9 inhibitors
- CYP2C9 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-07264660 CI brief — competitive landscape report
- Pf-07264660 updates RSS · CI watch RSS
- Pfizer portfolio CI